Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989078 | 0.85 | GRIN2D (0.40) | KDM4ERECQLGRIN2DGRIN3BGRIN1 | |
| SCHEMBL6580601 | 0.77 | ALDH1A1 (0.46) | KDM4ERECQLRAB9ASMN1; SMN2LMNA | |
| SCHEMBL9388261 | 0.76 | KDM4E (0.55) | KDM4ERECQLRAB9ASMN1; SMN2LMNA | |
| SCHEMBL29901709 | 0.76 | KDM4E (0.57) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6947094 | 0.76 | KDM4E (0.57) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL23882113 | 0.75 | KDM4E (0.50) | KDM4ERECQLRAB9ASMN1; SMN2LMNA | |
| SCHEMBL988602 | 0.74 | ALDH1A1 (0.38) | KDM4ERECQLSMN1; SMN2LMNAGAA | |
| SCHEMBL8199108 | 0.73 | ALDH1A1 (0.40) | KDM4ERECQLGRIN2DGRIN3BGRIN1 | |
| SCHEMBL29900596 | 0.73 | KDM4E (0.67) | KDM4ERECQLLMNATUBB4ATUBB | |
| SCHEMBL6584384 | 0.73 | KDM4E (0.51) | KDM4ERECQLGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595966-B1 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | BTG INT LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| US-8809526-B2 | Synthesis of cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809526-B2 | Synthesis of cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2213664-B1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG INT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| EP-2213664-B1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG INT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| US-8552016-B2 | Anti-cancer cyclopenta(g)quinazoline compounds | BTG INTERNATIONAL LIMITED (GB) | 2013-10-08 | — | — | US | disclosed |
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | ONYX PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8486955-B2 | Anti-cancer cyclopenta [g] quinazoline compounds | BTG INTERNATIONAL LIMITED (GB) | 2013-07-16 | — | — | US | disclosed |
| WO-2012011939-A2 | SYNTHESIS OF CYCLOPENTAQUINAZOLINES | ONYX PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| EP-1421105-A1 | ANTI-CANCER CYCLOPENTA[G]QUINAZOLINE COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 2004-05-26 | — | — | EP | disclosed |
| EP-1420809-A1 | USE OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES FOR TREATING CANCER | BTG International Limited (GB) | 2004-05-26 | — | — | EP | disclosed |
| EP-1421069-A1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES | BTG International Limited (GB) | 2004-05-26 | — | — | EP | disclosed |
| EP-1155012-B1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | CANCER REC TECH LTD (GB) | 2004-04-14 | — | — | EP | disclosed |
| US-6699861-B1 | ANTI-CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-03-02 | — | — | US | disclosed |
| WO-2003020748-A1 | ANTI-CANCER CYCLOPENTA[G]QUINAZOLINE COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020706-A1 | PROCESS FOR THE PREPARATION OF CYCLOPENTA[g]QUINAZOLINE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020300-A1 | USE OF CYCLOPENTA[G]QUINAZOLINE DERIVATIVES FOR TREATING CANCER | BTG INTERNATIONAL LIMITED (GB) | 2003-03-13 | — | — | WO | disclosed |
| EP-1155012-A1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | Cancer Research Ventures Limited (GB) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050417-A1 | ANTI-CANCER DIHYDROQUINAZOLINE DERIVATIVES | CANCER RESEARCH VENTURES LIMITED (GB) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211082-A1 | Synthesis of Cyclopentaquinazolines | GLUL, QPCT, ASNS | KDM4E 2032/4885RECQL 1123/4885GRIN2D 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.